EMA recommends withdrawal of Adakveo
The European Medicines Agency is recommending that Adakveo (crizanlizumab), a medicine for preventing vaso-occlusive crises in patients with sickle cell disease, be withdrawn from the EU market. This follows data from a post-authorisation study showing little benefit and a higher rate of adverse events. Developed by Novartis, Adakveo was given a conditional approval on 28 October 2020. Full approval was contingent on positive data from the STAND follow-up study.